NYSE:CI
Cigna Group
A diversified global health services leader providing comprehensive medical, dental, and vision insurance alongside innovative healthcare management solutions.
Key Metrics
Investment Thesis
Bull Case
Cigna offers compelling value with its recent profitability recovery demonstrated by a 66% net income surge from 2024 to 2025, coupled with disciplined capital allocation through aggressive buybacks. The strategic expansion into digital health tools and integration of pharmacy services creates durable revenue streams that are less sensitive to traditional insurance cycle fluctuations. Investors gain exposure to an essential sector with pricing power that historically outpaces inflation during periods of economic stability.
Bear Case
The massive accumulated other comprehensive income loss of -$2.81B and significant non-operating losses suggest underlying volatility that could impact future earnings quality if market conditions deteriorate. Heavy reliance on government programs exposes the stock to political risk and potential benefit cuts that could disrupt steady revenue growth trajectories observed over the past five years. High operating expenses of $50.71B relative to gross profit margins leave limited cushion against unexpected increases in healthcare delivery costs or regulatory penalties.
About Cigna Group
Cigna Group is a global health services company operating primarily in the United States, serving individuals, employers, governments, and organizations with comprehensive healthcare solutions. The company leverages its extensive network of providers and data analytics to deliver medical insurance plans, dental coverage, vision care, and pharmacy benefits while managing population health outcomes. Key products include employer-sponsored group health plans, Medicare Advantage offerings, and direct-to-consumer consumer-focused health services.
Analysis
Management Discussion
The company reported a strong rebound in net profit of $6.29B for the latest year following a volatile 2024, with total revenue reaching $274.90B reflecting successful premium growth and market share gains. Cash flow from operations remained robust at $9.60B, allowing significant share repurchases of $3.62B and dividends of $1.61B to return capital while maintaining a healthy cash balance of $7.68B. However, the large non-cash adjustments of -$3.32B and accumulated other comprehensive losses indicate ongoing accounting complexities regarding intangible assets like goodwill.
Industry Overview
The global health insurance sector is characterized by intense competition among major players like UnitedHealth Group and Elevance Health, driving consolidation and technological innovation. Regulatory environments vary significantly across regions, with ongoing debates over drug pricing reforms and network adequacy standards shaping industry profitability. Technological advancements in AI-driven underwriting and telehealth integration are becoming standard expectations for maintaining competitive relevance.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $180.52B | $195.26B | $247.12B | $274.90B |
| Cost of Revenue | $124.83B | $133.80B | $182.51B | $214.99B |
| Gross Profit | $55.68B | $61.46B | $64.61B | $59.91B |
| Operating Expenses | $47.27B | $52.93B | $55.20B | $50.71B |
| Operating Income | $8.41B | $8.54B | $9.42B | $9.20B |
| G&A | $13.19B | $14.82B | $14.84B | $14.62B |
| Stock-Based Comp | $264.0M | $286.0M | $308.0M | $291.0M |
| D&A | $2.94B | $3.04B | $2.77B | $2.77B |
| Amortization | $1.88B | $1.82B | $1.70B | $1.74B |
| Other OpEx | $34.08B | $38.11B | $40.35B | $36.09B |
| Non-Operating Income | $-61.0M | $-3.02B | $-4.15B | $-1.42B |
| Pre-Tax Income | $8.35B | $5.51B | $5.27B | $7.78B |
| Income Tax | $1.61B | $141.0M | $1.49B | $1.49B |
| Continuing Ops | $6.75B | $5.37B | $3.78B | $6.29B |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $6.75B | $5.37B | $3.78B | $6.29B |
| Minority Interest | $78.0M | $208.0M | $344.0M | $331.0M |
| Net to Common | $6.67B | $5.16B | $3.43B | $5.96B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $30.12B | $37.35B | $48.87B | $47.81B |
| Cash & Equivalents | $5.92B | $7.82B | $7.55B | $7.68B |
| Marketable Securities | $905.0M | $925.0M | $665.0M | $1.06B |
| Inventory | $4.78B | $5.64B | $6.69B | $7.34B |
| Other Current Assets | $18.51B | $22.96B | $33.96B | $31.74B |
| Long-Term Assets | $113.81B | $115.41B | $107.01B | $110.11B |
| PP&E (Net) | $3.77B | — | — | $3.65B |
| Intangibles | $32.49B | $30.86B | $29.42B | $28.56B |
| Goodwill | $45.81B | $44.26B | $44.37B | $44.92B |
| Operating Leases | $375.0M | $370.0M | — | — |
| LT Investments | $16.29B | $17.98B | $15.13B | $18.47B |
| Other LT Assets | $15.07B | $21.93B | $18.10B | $14.50B |
| Total Assets | $143.93B | $152.76B | $155.88B | $157.92B |
| Current Liabilities | $41.23B | $48.72B | $57.98B | $56.34B |
| Accounts Payable | $7.78B | $8.55B | $9.29B | $10.66B |
| Current Leases | $114.0M | $105.0M | — | — |
| Other Current Liab | $33.34B | $40.06B | $48.69B | $45.68B |
| Long-Term Liabilities | $57.75B | $57.69B | $56.66B | $59.70B |
| LT Operating Leases | $346.0M | $340.0M | — | — |
| Other LT Liab | $57.41B | $56.12B | $55.78B | $59.70B |
| Total Liabilities | $98.98B | $106.41B | $114.64B | $116.05B |
| Shareholders' Equity | $44.95B | $46.35B | $41.24B | $41.87B |
| Retained Earnings | $37.87B | $41.65B | $43.52B | $47.87B |
| AOCI | $-1.40B | $-1.86B | $-2.34B | $-2.81B |
| Treasury Stock | $21.84B | $24.24B | $31.44B | $35.14B |
| Total L&E | $143.93B | $152.76B | $155.88B | $157.92B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $6.75B | $5.37B | $3.78B | $6.29B |
| Non-Cash Adjustments | $-1.87B | $1.59B | $-1.03B | $-3.32B |
| Working Capital Changes | $3.78B | $4.85B | $7.62B | $6.63B |
| Cash from Operations | $8.66B | $11.81B | $10.36B | $9.60B |
| Cash from Investing | $3.10B | $-5.17B | $-2.10B | $-4.41B |
| Debt Issuances | $0 | $1.49B | $4.46B | $4.46B |
| Debt Repayments | $500.0M | $2.97B | $3.00B | $4.20B |
| Share Buybacks | $7.61B | $2.28B | $7.03B | $3.62B |
| Dividends Paid | $1.38B | $1.45B | $1.57B | $1.61B |
| Cash from Financing | $-11.24B | $-4.29B | $-7.65B | $-6.42B |
| FX Effect | $-86.0M | $16.0M | $-20.0M | $32.0M |
| Net Change in Cash | $428.0M | $2.36B | $594.0M | $-1.20B |
| Beginning Cash | $5.12B | $5.98B | $7.87B | $7.59B |
| Ending Cash | $5.98B | $7.87B | $7.59B | $7.74B |
Frequently Asked Questions
How does Cigna Group make money?
Revenue is driven by commercial and individual health benefit plans, government programs including Medicare Advantage, and pharmacy and specialty services such as CVS Health partnership offerings. The company also generates significant income from its managed care networks and digital health platforms that support preventive care and chronic disease management.
What are the main risks for CI?
Rising medical inflation and unpredictable claim costs could erode operating margins despite premium growth, particularly in high-cost markets like California. Regulatory changes in Medicare Advantage reimbursement rates or Medicaid managed care policies pose significant threats to government segment profitability. Cybersecurity vulnerabilities related to sensitive patient data and potential antitrust scrutiny regarding its CVS partnership could lead to substantial fines or operational restrictions.
What is CI's competitive advantage?
Cigna benefits from a vast proprietary data network enabling superior risk adjustment and personalized care plans, creating a high barrier to entry for competitors. Its strategic acquisition of Carelon Health and integration with CVS Health provide deep pharmacy distribution channels and specialized care capabilities that enhance margin expansion potential. Strong brand recognition and long-term relationships with large employer clients ensure consistent renewal rates and pricing power in the competitive insurance landscape.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.